Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Antibodies (Basel, Switzerland)
|
March 27, 2024
Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies
Hannah V Giles, Kamaraj Karunanithi
British Journal of Haematology
|
August 16, 2023
Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper
Simon Stern, Satarupa Chaudhuri, Mark Drayson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2009
Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia
Saman Hewamana, Thet Thet Lin, Clare Rowntree, et al.
Expert Review of Cardiovascular Therapy
|
February 7, 2025
Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective
Gemina Doolub, Avraham Raichman, Dmitry Abramov, et al.
Ejhaem
|
December 18, 2024
The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service
Rakesh Popat, Supratik Basu, Sarah Henshaw, et al.
Cancers
|
July 14, 2023
Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
Stella Bowcock, Catherine Atkin, Gulnaz Iqbal, et al.
British Journal of Haematology
|
December 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial
Matthew W Jenner, Charlotte Pawlyn, Faith E Davies, et al.
British Journal of Haematology
|
February 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis
Annabel McMillan, Supratik Basu, Kamaraj Karunanithi, et al.
Leukemia
|
December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
James Croft, Sidra Ellis, Amy L Sherborne, et al.
The Lancet. Oncology
|
December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Antibodies (Basel, Switzerland)
|
March 27, 2024
Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies
Hannah V Giles, Kamaraj Karunanithi
British Journal of Haematology
|
August 16, 2023
Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper
Simon Stern, Satarupa Chaudhuri, Mark Drayson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2009
Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia
Saman Hewamana, Thet Thet Lin, Clare Rowntree, et al.
Expert Review of Cardiovascular Therapy
|
February 7, 2025
Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective
Gemina Doolub, Avraham Raichman, Dmitry Abramov, et al.
Ejhaem
|
December 18, 2024
The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service
Rakesh Popat, Supratik Basu, Sarah Henshaw, et al.
Cancers
|
July 14, 2023
Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
Stella Bowcock, Catherine Atkin, Gulnaz Iqbal, et al.
British Journal of Haematology
|
December 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial
Matthew W Jenner, Charlotte Pawlyn, Faith E Davies, et al.
British Journal of Haematology
|
February 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis
Annabel McMillan, Supratik Basu, Kamaraj Karunanithi, et al.
Leukemia
|
December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
James Croft, Sidra Ellis, Amy L Sherborne, et al.
The Lancet. Oncology
|
December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Page
of 2